1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Ladaviere, L. Deleage, G. Montserret, R. Dalbon, P. Jolivet, M. Penin, F. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 Structural Analysis of the Immunodominant Antigenic Region of the Hepatitis C Virus Capsid Protein by NMR 10.2210/pdb1cwx/pdb pdb_00001cwx 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4909.684 HEPATITIS C VIRUS CAPSID PROTEIN N-TERMINAL FRAGMENT 1 syn polymer no no STNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLG STNPKPQRKTKRNTNRRPQDVKFPGGGQIVGGVYLLPRRGPRLG A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n database_2 pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 1999-08-30 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession RCSB Y RCSB 1999-08-27 REL REL THE PROTEIN WAS CHEMICALLY SYNTHESIZED. THIS SEQUENCE OCCURS NATURALLY IN HEPATITIS C VIRUS (GENOTYPE 1A ISOLATE H77).. sample THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES. MOST CONVERGENT STRUCTURES AT THE LEVEL OF BOTH HELICES. NOTE THAT 23 STRUCTURES OVER 50 HAD NO RESTRAINT VIOLATION > 0.5 ANGSTROM. 50 4 2D NOESY DQF-COSY 2D ROESY 2D TOCSY 0.1M NACL 5.9 AMBIENT 293 K DISTANCE GEOMETRY SIMULATED ANNEALING MOLECULAR DYNAMICS MATRIX RELAXATION 4 closest to the average 40% D2-TRIFLUOROETHANOL;0.01M SODIUM PHOSPHATE;0.1M NACL VARIAN collection VNMR 5.1 VARIAN data analysis VNMR 5.1 BRUNGER refinement X-PLOR 3.1 BRUNGER structure solution X-PLOR 3.1 500 Varian UNITYPLUS SER 1 n 1 SER 1 A THR 2 n 2 THR 2 A ASN 3 n 3 ASN 3 A PRO 4 n 4 PRO 4 A LYS 5 n 5 LYS 5 A PRO 6 n 6 PRO 6 A GLN 7 n 7 GLN 7 A ARG 8 n 8 ARG 8 A LYS 9 n 9 LYS 9 A THR 10 n 10 THR 10 A LYS 11 n 11 LYS 11 A ARG 12 n 12 ARG 12 A ASN 13 n 13 ASN 13 A THR 14 n 14 THR 14 A ASN 15 n 15 ASN 15 A ARG 16 n 16 ARG 16 A ARG 17 n 17 ARG 17 A PRO 18 n 18 PRO 18 A GLN 19 n 19 GLN 19 A ASP 20 n 20 ASP 20 A VAL 21 n 21 VAL 21 A LYS 22 n 22 LYS 22 A PHE 23 n 23 PHE 23 A PRO 24 n 24 PRO 24 A GLY 25 n 25 GLY 25 A GLY 26 n 26 GLY 26 A GLY 27 n 27 GLY 27 A GLN 28 n 28 GLN 28 A ILE 29 n 29 ILE 29 A VAL 30 n 30 VAL 30 A GLY 31 n 31 GLY 31 A GLY 32 n 32 GLY 32 A VAL 33 n 33 VAL 33 A TYR 34 n 34 TYR 34 A LEU 35 n 35 LEU 35 A LEU 36 n 36 LEU 36 A PRO 37 n 37 PRO 37 A ARG 38 n 38 ARG 38 A ARG 39 n 39 ARG 39 A GLY 40 n 40 GLY 40 A PRO 41 n 41 PRO 41 A ARG 42 n 42 ARG 42 A LEU 43 n 43 LEU 43 A GLY 44 n 44 GLY 44 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A ARG 8 0.318 SIDE CHAIN 1 A ARG 12 0.309 SIDE CHAIN 1 A ARG 16 0.289 SIDE CHAIN 1 A ARG 17 0.239 SIDE CHAIN 1 A ARG 38 0.305 SIDE CHAIN 1 A ARG 39 0.241 SIDE CHAIN 1 A ARG 42 0.285 SIDE CHAIN 2 A ARG 8 0.310 SIDE CHAIN 2 A ARG 12 0.270 SIDE CHAIN 2 A ARG 16 0.084 SIDE CHAIN 2 A ARG 17 0.263 SIDE CHAIN 2 A ARG 38 0.299 SIDE CHAIN 2 A ARG 39 0.196 SIDE CHAIN 2 A ARG 42 0.298 SIDE CHAIN 3 A ARG 8 0.254 SIDE CHAIN 3 A ARG 12 0.230 SIDE CHAIN 3 A ARG 16 0.310 SIDE CHAIN 3 A ARG 17 0.191 SIDE CHAIN 3 A ARG 38 0.273 SIDE CHAIN 3 A ARG 39 0.200 SIDE CHAIN 3 A ARG 42 0.315 SIDE CHAIN 4 A ARG 8 0.317 SIDE CHAIN 4 A ARG 12 0.311 SIDE CHAIN 4 A ARG 17 0.225 SIDE CHAIN 4 A ARG 38 0.315 SIDE CHAIN 4 A ARG 39 0.294 SIDE CHAIN 4 A ARG 42 0.249 SIDE CHAIN 1 A THR 2 -179.90 89.37 1 A LYS 5 164.29 -51.52 1 A LYS 9 179.45 -49.94 1 A THR 10 -85.71 -80.39 1 A ARG 12 63.23 -174.80 1 A ASN 13 -45.02 169.28 1 A THR 14 -173.66 -38.29 1 A ARG 17 120.76 -45.57 1 A GLN 19 -86.71 41.26 1 A ASP 20 -155.39 -43.16 1 A GLN 28 -48.14 -10.28 1 A ILE 29 80.37 -6.72 1 A ARG 39 -52.77 94.09 2 A THR 2 59.98 -89.01 2 A ASN 3 -164.66 84.54 2 A LYS 9 -173.71 149.65 2 A LYS 11 -173.05 -53.35 2 A ARG 12 61.86 129.09 2 A THR 14 -170.67 -43.55 2 A ASN 15 -164.65 116.25 2 A ARG 17 161.42 -57.26 2 A GLN 19 -91.27 43.99 2 A ASP 20 -151.52 -39.98 2 A PRO 24 -77.21 -72.97 2 A ILE 29 83.26 -12.09 2 A ARG 38 -87.58 39.25 3 A ASN 3 -176.65 96.18 3 A LYS 9 -150.93 -90.03 3 A THR 10 79.96 -73.36 3 A LYS 11 62.59 127.95 3 A ARG 12 50.47 -179.69 3 A ASN 13 -149.98 -66.37 3 A ARG 17 147.93 -57.96 3 A GLN 19 -89.49 40.60 3 A ASP 20 -153.89 -43.06 3 A ARG 39 -50.06 96.19 4 A THR 2 -157.98 -74.63 4 A LYS 5 61.44 79.68 4 A GLN 7 -75.83 -90.04 4 A ARG 8 -174.09 99.75 4 A LYS 9 -163.13 -88.10 4 A THR 10 174.71 172.92 4 A LYS 11 -58.20 177.77 4 A ASN 15 -47.39 92.84 4 A ARG 17 124.49 -47.50 4 A GLN 19 -89.37 44.80 4 A ASP 20 -157.26 -41.81 4 A GLN 28 -135.95 -33.67 4 A ILE 29 85.34 -12.95 4 A PRO 37 -77.22 -100.62 4 A ARG 38 -94.72 -106.04 4 A LEU 43 -118.71 61.15 SOLUTION STRUCTURE OF THE HEPATITIS C VIRUS N-TERMINAL CAPSID PROTEIN 2-45 [C-HCV(2-45)] 1 N N VIRAL PROTEIN HELIX-LOOP-HELIX, Viral protein POLG_HCVH UNP 1 P27958 2 45 1CWX 1 44 P27958 A 1 1 44 1 P 1